Agenus (NASDAQ:AGEN – Get Free Report) is expected to release its earnings data before the market opens on Tuesday, March 11th. Analysts expect Agenus to post earnings of ($2.36) per share and revenue of $30.09 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.
Agenus Stock Down 10.9 %
Shares of Agenus stock opened at $2.54 on Tuesday. Agenus has a 52 week low of $2.50 and a 52 week high of $19.69. The business’s fifty day simple moving average is $3.30 and its 200-day simple moving average is $3.98. The firm has a market cap of $59.59 million, a PE ratio of -0.23 and a beta of 1.31.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research note on Wednesday, January 22nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Agenus has a consensus rating of “Hold” and an average target price of $10.00.
Agenus Company Profile
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Read More
- Five stocks we like better than Agenus
- What is a Death Cross in Stocks?
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Stock Sentiment Analysis: How it Works
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- What is a buyback in stocks? A comprehensive guide for investors
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
